bevirimat
Jump to navigation
Jump to search
Introduction
Investigational agent
Indications
- adjunctive treatment of HIV1 infection*
* resistance is high:
- 32% of treatment-naive patients
- 25% of patients with resistance to reverse transcriptase inhibitors
- 45% among patients with resistance to HIV protease inhibitors
Mechanism of action
- HIV integrase inhibitor (similar to raltegravir)
More general terms
Additional terms
References
- ↑ Verheyen J et al. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS 2009 Nov 18 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19926962 <Internet> http://tinyurl.com/yej8u4w